A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.Most Read from BloombergTrump DEI Purge Hits Afforda

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics ( VKTX 10.22%) and Roche Holdings ( RHHBY 3.62%), up 11.3% and 4%, respectively, through 10:05 a.m. ET today, are behind it.